Clinical Trial of Investigational Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma (B-NHL) Published in The Lancet

NORTH CHICAGO, Ill., and COPENHAGEN, Denmark, Sept, 9, 2021 /PRNewswire/ — AbbVie (NYSE: ABBV) and Genmab A/S (Nasdaq: GMAB) today announced The Lancet published the results of the dose escalation part of the Phase 1/2 EPCORE™ NHL-1 first-in-human (FIH) dose escalation and cohort expansion clinical trial evaluating safety and preliminary efficacy of the investigational therapy epcoritamab (DuoBody®-CD3xCD20) in patients with relapsed/refractory B-cell non-Hodgkin’s lymphoma (B-NHL). The full manuscript is available on The Lancet’s website. Epcoritamab is being co-developed by Genmab and AbbVie.

close

Get every new post delivered right to your inbox.

Original Source